Since garnering its eye-popping financing in November 2021, the protein therapeutics developer has focused on building its pipeline, which is on track for 14 preclinical programs this year, and has also expanded its platform beyond creating antibodies and enzymes into bispecifics and cell therapies . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post Engineerable Biology: Generate Builds Pipeline, Expands Modalities appeared first on GEN – Genetic Engineering and Biotechnology News.
